Oxford Vaccine Group is leading the trail for the Nipah virus vaccine, and the group is backend with the support of CEPI in terms of funds.
The life-threatening Nipah virus might finally have an antidote now, as the Oxford vaccine group has started its human phase trials following a preclinical trial.
A representative for the University's Pandemic Sciences Institute told news agency Reuters that 52 participants in the human trial, which the University of Oxford is carrying out, will evaluate immune response and safety in people between the ages of 18 and 55.
The participants received the first dose of the vaccine during the last week. As there is no existing vaccine for the virus, a similar kind of technology will be used that was used to produce AstraZeneca's and Serum Institute of India's Covid-19 shots.
Dr In-Kyu Yoon, an executive at the Coalition for Epidemic Preparedness Innovations (CEPI) said, "Nipah has epidemic potential, with its fruit bat hosts found in areas home to over two billion people. This trial is a step forward in efforts to build a suite of tools to protect against this killer virus." CEPI is a global coalition that supports the development of vaccines against emerging infectious diseases, is funding the human testing.
Oxford Vaccine Group is leading the trail for the Nipah virus vaccine, and the group is backend with the support of CEPI in terms of funds. Humans can contract the Nipah virus infection by coming into contact with infected animals, such as pigs and bats. The World Health Organization states that transmission can also occur through direct contact with an infected person, though this is less frequent.
It was originally discovered in Malaysia some 25 years ago, and since then, outbreaks have occurred in Bangladesh, India, and Singapore.
Kerala, India, saw its fourth Nipah outbreak in five years in September 2023. Six laboratory-confirmed cases—two of which resulted in deaths—were reported by the Ministry of Health and Family Welfare for the Kozhikode district.
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
 "Oxford Vaccine Group begins human trial of Nipah virus vaccine")
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}
)
){kind=small}
){kind=small}
)
)
)
)
)
){kind=small}
){kind=small}
){kind=small}
){kind=small}
){kind=small}